Aditi Sinha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aditi Sinha has a total of 181 co-authors. Here are the top co-authors by number of shared publications:
Arvind Bagga
21 shared publicationsPankaj Hari
14 shared publicationsPriyanka Khandelwal
Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India
9 shared publications- Arvind Bagga
Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
7 shared publications Menka Yadav
7 shared publicationsJitendra Meena
Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India
4 shared publications
Latest Publications
- 11 July 2026
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 93 (8) , 1-2
Spot Urine Calcium to Creatinine Ratio: Age-Specific Reference Ranges
- 11 July 2026
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 93 (8) , 1-2
Spot Urine Calcium to Creatinine Ratio: Age-Specific Reference Ranges
- Open Access
- 22 April 2026
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 93 (5) , 505-506
Pediatric Nephrology in Clinical Practice
- 22 April 2026
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 93 (5) , 505-506
Open AccessPediatric Nephrology in Clinical Practice
- 17 March 2026
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 93 (4) , 353-354
CAKUT: Current Understanding and Future Directions
- 17 March 2026
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 93 (4) , 353-354
CAKUT: Current Understanding and Future Directions
- 14 October 2025
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (2) , 413-422
Randomized controlled trial on efficacy and safety of torsemide versus furosemide in patients with nephrotic syndrome
Background Torsemide is preferred to furosemide in adults with heart failure for its higher bioavailability and longer half-life. Evidence of benefit in children is limited to uncontrolled studies. Methods This single-center, open-label, randomized controlled trial compared the superiority of oral therapy with torsemide administered at a dose of 0.25–0.5 mg/kg twice daily, to furosemide 1–1.5 mg/kg twice daily for 48-h, in inducing diuresis in patients, 3–18 years-old, with nephrotic syndrome and moderate to severe edema without hypovolemia (CTRI/2023/10/058799). Secondary outcomes included proportions of patients with adequate and inadequate diuresis, treatment failure, treatment-emergent adverse events or serious adverse events (TEAE, SAE), percentage weight loss, natriuresis and free water clearance. Results Of 173 patients screened, 25 patients each, with no significant baseline differences, were randomized to receive torsemide or furosemide. Nine patients in each group received 4 doses per protocol; others received fewer doses due to treatment failure or TEAE. On intention-to-treat analyses, patients in the torsemide and furosemide groups had similar urine output over 48-h (mean difference, MD 0.42; 95% CI -0.39,1.23 ml/kg/hr) and comparable proportions of patients had adequate diuresis (MD 20%; -3.7, 43.7%), inadequate diuresis (MD 16%; -41, 9.5%), treatment failure (MD -4%; -17.1, 9.1%), and TEAE or SAE. There were no differences in weight loss (MD 0.82; -2.2, 3.8%), natriuresis (MD -2.9; -74.4, 68.5 mEq/day) and free water clearance (MD 150.1; -266.1, 567.2 ml/day). Per-protocol analyses confirmed no intergroup differences. Conclusions Torsemide is not superior to furosemide in inducing diuresis in children with nephrotic syndrome with moderate to severe edema. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- 14 October 2025
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (2) , 413-422
Randomized controlled trial on efficacy and safety of torsemide versus furosemide in patients with nephrotic syndrome
Background Torsemide is preferred to furosemide in adults with heart failure for its higher bioavailability and longer half-life. Evidence of benefit in children is limited to uncontrolled studies. Methods This single-center, open-label, randomized controlled trial compared the superiority of oral therapy with torsemide administered at a dose of 0.25–0.5 mg/kg twice daily, to furosemide 1–1.5 mg/kg twice daily for 48-h, in inducing diuresis in patients, 3–18 years-old, with nephrotic syndrome and moderate to severe edema without hypovolemia (CTRI/2023/10/058799). Secondary outcomes included proportions of patients with adequate and inadequate diuresis, treatment failure, treatment-emergent adverse events or serious adverse events (TEAE, SAE), percentage weight loss, natriuresis and free water clearance. Results Of 173 patients screened, 25 patients each, with no significant baseline differences, were randomized to receive torsemide or furosemide. Nine patients in each group received 4 doses per protocol; others received fewer doses due to treatment failure or TEAE. On intention-to-treat analyses, patients in the torsemide and furosemide groups had similar urine output over 48-h (mean difference, MD 0.42; 95% CI -0.39,1.23 ml/kg/hr) and comparable proportions of patients had adequate diuresis (MD 20%; -3.7, 43.7%), inadequate diuresis (MD 16%; -41, 9.5%), treatment failure (MD -4%; -17.1, 9.1%), and TEAE or SAE. There were no differences in weight loss (MD 0.82; -2.2, 3.8%), natriuresis (MD -2.9; -74.4, 68.5 mEq/day) and free water clearance (MD 150.1; -266.1, 567.2 ml/day). Per-protocol analyses confirmed no intergroup differences. Conclusions Torsemide is not superior to furosemide in inducing diuresis in children with nephrotic syndrome with moderate to severe edema. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- 23 September 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (7) , e70177
ABO Incompatible Kidney Transplantation in Indian Children
Background: Kidney transplantation programs in developing countries chiefly depends on live donors, and waiting lists are long for patients lacking ABO compatible ( ABOc ) donors. ABO incompatible ( ABOi ) transplantation enhances the donor pool. We report our experience of ABOi kidney transplantation in children. Methods: We screened medical records of ABOi and ABOc kidney transplantation performed at this center between January 2019 to December 2023. For desensitization of ABOi kidney allograft recipients a combination of rituximab and either immunoadsorption or plasma exchange along with IVIg was used. Induction regimen comprised either basiliximab or ATG , followed by maintenance therapy with tacrolimus, mycophenolate mofetil and prednisolone. We retrieved data on recipient and donor characteristics, immunosuppression, and post‐transplant complications. Allograft and patient survival were estimated using Kaplan–Meier survival analysis. Results: During the 5‐years, 7 ABOi and 46 ABOc kidney transplantation were performed. The mean follow up duration was 24.9 ± 17.1 months in ABOi group and 30.3 ± 18.8 months in ABOc group. Patient age, native kidney disease, donor profile and other characteristics were comparable. Rejection free graft survival was similar between ABOi and ABOc groups ( p = 0.88). Median ( IQR ) eGFR at last follow up was 61.4 (46.6, 74.3) ml/min/1.73 m 2 in ABOi group and 50.9 (39.7, 68.9) ml/min/1.73 m 2 in ABOc group ( p = 0.23). Patients and graft survival rates were similar in both groups. Conclusions: Our findings suggest that ABOi kidney transplantation in children in India is feasible and associated with satisfactory outcomes P.
- 23 September 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (7) , e70177
ABO Incompatible Kidney Transplantation in Indian Children
Background: Kidney transplantation programs in developing countries chiefly depends on live donors, and waiting lists are long for patients lacking ABO compatible ( ABOc ) donors. ABO incompatible ( ABOi ) transplantation enhances the donor pool. We report our experience of ABOi kidney transplantation in children. Methods: We screened medical records of ABOi and ABOc kidney transplantation performed at this center between January 2019 to December 2023. For desensitization of ABOi kidney allograft recipients a combination of rituximab and either immunoadsorption or plasma exchange along with IVIg was used. Induction regimen comprised either basiliximab or ATG , followed by maintenance therapy with tacrolimus, mycophenolate mofetil and prednisolone. We retrieved data on recipient and donor characteristics, immunosuppression, and post‐transplant complications. Allograft and patient survival were estimated using Kaplan–Meier survival analysis. Results: During the 5‐years, 7 ABOi and 46 ABOc kidney transplantation were performed. The mean follow up duration was 24.9 ± 17.1 months in ABOi group and 30.3 ± 18.8 months in ABOc group. Patient age, native kidney disease, donor profile and other characteristics were comparable. Rejection free graft survival was similar between ABOi and ABOc groups ( p = 0.88). Median ( IQR ) eGFR at last follow up was 61.4 (46.6, 74.3) ml/min/1.73 m 2 in ABOi group and 50.9 (39.7, 68.9) ml/min/1.73 m 2 in ABOc group ( p = 0.23). Patients and graft survival rates were similar in both groups. Conclusions: Our findings suggest that ABOi kidney transplantation in children in India is feasible and associated with satisfactory outcomes P.
- 9 September 2025
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (1) , 125-134
Spectrum of kidney disease in pediatric sarcoidosis
Background Kidney involvement in pediatric sarcoidosis is rare and often underrecognized, leading to diagnostic delays and treatment challenges. We report six patients with renal sarcoidosis to highlight their diverse presentations and outcomes and challenges in management. Methods Medical records of patients diagnosed with renal sarcoidosis during 2020–24 were reviewed. Sarcoidosis was diagnosed based on clinical and histological features and exclusion of alternative causes and managed according to unit protocols. Information on clinical features, laboratory and radiologic findings, histopathology, treatment, and follow-up were compiled. Results We present six patients with sarcoidosis, presenting with kidney involvement at the age of 1.5–14 years, and followed up for 7–138 months. All patients had acute kidney injury (AKI) of whom two required hemodialysis. Proteinuria was present in all patients, while four patients had microscopic hematuria or leukocyturia. Hypercalcemia with hypercalciuria, distal renal tubular acidosis, and nephrocalcinosis were seen in five, two, and one case, respectively. Granulomatous interstitial nephritis was confirmed histologically in all cases. While initial therapy with corticosteroids led to clinical remission in all cases, five patients had nine relapses, necessitating second-line immunosuppression with mycophenolate mofetil, azathioprine, or methotrexate; one patient received antitumor necrosis factor therapy. Median eGFR at last follow up was 59.7 (range 12.7-132) ml/min/1.73 m2; three progressed to chronic kidney disease (CKD) stages G3–G5. Conclusions Kidney involvement in pediatric sarcoidosis manifests in diverse forms, ranging from isolated biochemical abnormalities to severe AKI. While prompt immunosuppression might preserve kidney function, patients require close monitoring for relapses, and progression to CKD. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- 9 September 2025
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (1) , 125-134
Spectrum of kidney disease in pediatric sarcoidosis
Background Kidney involvement in pediatric sarcoidosis is rare and often underrecognized, leading to diagnostic delays and treatment challenges. We report six patients with renal sarcoidosis to highlight their diverse presentations and outcomes and challenges in management. Methods Medical records of patients diagnosed with renal sarcoidosis during 2020–24 were reviewed. Sarcoidosis was diagnosed based on clinical and histological features and exclusion of alternative causes and managed according to unit protocols. Information on clinical features, laboratory and radiologic findings, histopathology, treatment, and follow-up were compiled. Results We present six patients with sarcoidosis, presenting with kidney involvement at the age of 1.5–14 years, and followed up for 7–138 months. All patients had acute kidney injury (AKI) of whom two required hemodialysis. Proteinuria was present in all patients, while four patients had microscopic hematuria or leukocyturia. Hypercalcemia with hypercalciuria, distal renal tubular acidosis, and nephrocalcinosis were seen in five, two, and one case, respectively. Granulomatous interstitial nephritis was confirmed histologically in all cases. While initial therapy with corticosteroids led to clinical remission in all cases, five patients had nine relapses, necessitating second-line immunosuppression with mycophenolate mofetil, azathioprine, or methotrexate; one patient received antitumor necrosis factor therapy. Median eGFR at last follow up was 59.7 (range 12.7-132) ml/min/1.73 m2; three progressed to chronic kidney disease (CKD) stages G3–G5. Conclusions Kidney involvement in pediatric sarcoidosis manifests in diverse forms, ranging from isolated biochemical abnormalities to severe AKI. While prompt immunosuppression might preserve kidney function, patients require close monitoring for relapses, and progression to CKD. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- Open Access
Polygenic Risk Scores and HLA Class II Variants are Biomarkers of Corticosteroid Response in Childhood Nephrotic Syndrome
Introduction: Nephrotic syndrome (NS), a common glomerular disease in children, is classified based on response to corticosteroid therapy as either steroid-sensitive nephrotic syndrome (SSNS), or steroid-resistant nephrotic syndrome (SRNS). However, there are currently no reliable predictors of therapy response at initial clinical presentation. Methods: We conducted genome-wide association studies, developed polygenic risk scores (PRS) for therapy response and analyzed classical HLA alleles in 1,997 (994 discovery and 1,003 replication/validation cohorts) previously unstudied children with NS and 3,558 ancestry-matched controls. Results: A significant association with HLA loci defined by variants in HLA-DQB1, HLA-DRB1 , and HLA-DQA1 were found for SSNS (but not SRNS), along with a second immune-related SSNS locus: CLEC16A . A PRS that discriminates between SSNS and SRNS was validated in two independent cohorts. The HLA haplotype HLA-DRB1*07:01∼DQA1*02:01∼DQB1*02:02 was associated with ∼4 times the risk of developing SSNS. A model incorporating HLA haplotype, PRS score, and age at onset of the disease was the best predictor of steroid responsiveness with an AUC of 0.68-0.70 and an overall classification accuracy of SSNS versus SRNS of 67-71%. Conclusions: Our findings confirm that SSNS (unlike SRNS) is an immune-mediated HLA-associated disorder. The PRS for therapy response and HLA haplotype can serve as biomarkers and provide a foundation for more accurate diagnoses and tailored and individualized treatment. Translational statement: To identify biomarkers of pattern of steroid responsiveness in childhood-onset nephrotic syndrome, we carried out a case-control study that included over 4,000 samples, including 994 patients with NS in the discovery phase and an additional 1,003 cases from two independent replication cohorts. We identified significant risk of steroid-sensitive NS (SSNS) at HLA class II genes and CLEC16A (a gene important in the regulation of T and B lymphocytes). The HLA haplotype DRB1*07:01∼DQA1*02:01∼DQB1*02:02 was associated with four-fold increased odds of SSNS. A model incorporating HLA haplotype, polygenic risk score, and age at onset of the disease was the best predictor of steroid responsiveness providing useful delineation of steroid sensitivity from steroid resistance. In conclusion, age at onset of disease, HLA class II variants and polygenic risk scores are useful biomarkers of corticosteroid response in childhood NS and may serve as useful clinical decision support tools to guide treatment. Abstract Figure: Graphical Abstract
Open AccessPolygenic Risk Scores and HLA Class II Variants are Biomarkers of Corticosteroid Response in Childhood Nephrotic Syndrome
Introduction: Nephrotic syndrome (NS), a common glomerular disease in children, is classified based on response to corticosteroid therapy as either steroid-sensitive nephrotic syndrome (SSNS), or steroid-resistant nephrotic syndrome (SRNS). However, there are currently no reliable predictors of therapy response at initial clinical presentation. Methods: We conducted genome-wide association studies, developed polygenic risk scores (PRS) for therapy response and analyzed classical HLA alleles in 1,997 (994 discovery and 1,003 replication/validation cohorts) previously unstudied children with NS and 3,558 ancestry-matched controls. Results: A significant association with HLA loci defined by variants in HLA-DQB1, HLA-DRB1 , and HLA-DQA1 were found for SSNS (but not SRNS), along with a second immune-related SSNS locus: CLEC16A . A PRS that discriminates between SSNS and SRNS was validated in two independent cohorts. The HLA haplotype HLA-DRB1*07:01∼DQA1*02:01∼DQB1*02:02 was associated with ∼4 times the risk of developing SSNS. A model incorporating HLA haplotype, PRS score, and age at onset of the disease was the best predictor of steroid responsiveness with an AUC of 0.68-0.70 and an overall classification accuracy of SSNS versus SRNS of 67-71%. Conclusions: Our findings confirm that SSNS (unlike SRNS) is an immune-mediated HLA-associated disorder. The PRS for therapy response and HLA haplotype can serve as biomarkers and provide a foundation for more accurate diagnoses and tailored and individualized treatment. Translational statement: To identify biomarkers of pattern of steroid responsiveness in childhood-onset nephrotic syndrome, we carried out a case-control study that included over 4,000 samples, including 994 patients with NS in the discovery phase and an additional 1,003 cases from two independent replication cohorts. We identified significant risk of steroid-sensitive NS (SSNS) at HLA class II genes and CLEC16A (a gene important in the regulation of T and B lymphocytes). The HLA haplotype DRB1*07:01∼DQA1*02:01∼DQB1*02:02 was associated with four-fold increased odds of SSNS. A model incorporating HLA haplotype, polygenic risk score, and age at onset of the disease was the best predictor of steroid responsiveness providing useful delineation of steroid sensitivity from steroid resistance. In conclusion, age at onset of disease, HLA class II variants and polygenic risk scores are useful biomarkers of corticosteroid response in childhood NS and may serve as useful clinical decision support tools to guide treatment. Abstract Figure: Graphical Abstract
- Open Access
- 6 August 2025
- Published by Springer Nature in Indian Journal of Pediatrics
- p. 1
Anasarca in Juvenile Dermatomyositis: An Uncommon Presentation
- 6 August 2025
- Published by Springer Nature in Indian Journal of Pediatrics
- p. 1
Open AccessAnasarca in Juvenile Dermatomyositis: An Uncommon Presentation